Pseudomonas aeruginosa chromosomal β-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response

APMIS, Supplement

Volumn 111, Issue 116, 2003, Pages 4-47

  Ciofu, Oana ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; POLYMYXIN; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIUM ISOLATION; CHROMOSOME MARKER; CHRONIC DISEASE; CONFERENCE PAPER; CYSTIC FIBROSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FUTUROLOGY; GENETIC REGULATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; LUNG INFECTION; MEMBRANE VESICLE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0347504933     PISSN: 0903465X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (249)

1. Medeiros AA. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis 1997;24 Suppl 1:819-45.
2. Massova I, Mobashery S. Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases. Antimicrob Agents Chemother 1998;42(1):1-17.
3. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994;264(5157):375-82.
4. Ghuysen JM. Serine beta-lactamases and penicillin-binding proteins. Annu Rev Microbiol 1991;45:37-67.
5. Ghuysen JM. Molecular structures of penicillin-binding proteins and beta-lactamases. Trends Microbiol 1994;2(10):372-80.
6. Ghuysen JM, Charlier P, Coyette J, Duez C, Fonze E, Fraipont C, et al. Penicillin and beyond: evolution, protein fold, multimodular polypeptides, and multiprotein complexes. Microb Drug Resist 1996;2(2):163-75.
7. Massova I, Mobashery S. Structural and mechanistic aspects of evolution of beta-lactamases and penicillin-binding proteins. Curr Pharm Des 1999;5(11):929-37.
8. Arthur M, Depardieu F, Snaith HA, Reynolds PE, Courvalin P Contribution of VanY D,D-carboxypeptidase to glycopeptide resistance in Enterococcus faecalis by hydrolysis of peptidoglycan precursors. Antimicrob Agents Chemother 1994;38(9):1899-903.
9. Xu Y, Soto G, Adachi H, van der Linden MP, Keck W, Pratt RF. Relative specificities of a series of beta-lactam-recognizing enzymes towards the side-chains of penicillins and of acyclic thioldepsipeptides. Biochem J 1994;302(Pt 3):851-6.
10. Livermore DM. beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8(4):557-84.
11. Richmond MH, Sykes RB. The beta-lactamases of gram-negative bacteria and their possible physiological role. Adv Microb Physiol 1973;9:31-88.
12. Bush K. Classification of beta-lactamases: groups 1, 2a, 2b, and 2b'. Antimicrob Agents Chemother 1989;33(3): 264-70.
13. Bush K. Classification of beta-lactamases: groups 2c, 2d, 2e, 3, and 4. Antimicrob Agents Chemother 1989;33(3):271-6.
14. Morosini MI, Negri MC, Shoichet B, Baquero MR, Baquero F, Blazquez J. An extended-spectrum AmpC-type beta-lactamase obtained by in vitro antibiotic selection. FEMS Microbiol Lett 1998;165(1):85-90.
15. Lister PD, Gardner VM, Sanders CC. Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. Antimicrob Agents Chemother 1999;43(4):882-9.
16. Raimondi A, Sisto F, Nikaido H. Mutation in Serratia marcescens AmpC beta-lactamase producing high-level resistance to ceftazidime and cefpirome. Antimicrob Agents Chemother 2001;45(8):2331-9.
17. Bauernfeind A, Schneider I, Jungwirth R, Sahly H, Ullmann U. A novel type of AmpC beta-lactamase, ACC-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia. Antimicrob Agents Chemother 1999;43(8):1924-31.
18. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother 1997;41(3):563-9.
19. Marchese A, Arlet G, Schito GC, Lagrange PH, Philippon A. Characterization of FOX-3, an AmpC-type plasmid-mediated beta-lactamase from an Italian isolate of Klebsiella oxytoca. Antimicrob Agents Chemother 1998;42(2):464-7.
20. Winokur PL, Brueggemann A, DeSalvo DL, Hoffmann L, Apley MD, Uhlenhopp EK, et al. Animal and human multidrug-resistant, cephalosporin-resistant salmonella isolates expressing a plasmid-mediated CMY-2 AmpC beta-lactamase. Antimicrob Agents Chemother 2000;44(10):2777-83.
21. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39(6):1211-33.
22. Bush K, Mobashery S. How beta-lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention. Adv Exp Med Biol 1998;456:71-98.
23. Bush K. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001;32(7):1085-9.
24. Ambler RP. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci 1980;289(1036):321-31.
25. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14(4):933-51, table of contents.
26. Alekshun M, Levy S. Bacterial drug resistance: response to survival threats. In: Storz G, Hengee-Aronis R, editors. Bacterial Stress Responses. Washington, D. C: ASM Press; 2000. p. 323-366.
27. Chaibi EB, Sirot D, Paul G, Labia R. Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother 1999;43(4):447-58.
28. Poirel L, Weldhagen GF, Naas T, De Champs C, Dove MG, Nordmann P. GES-2, a class A beta-lactamase from Pseudomonas aeruginosa with increased hydrolysis of imipenem. Antimicrob Agents Chemother 2001;45(9):2598-603.
29. Osano E, Arakawa Y, Wacharotayankun R, Ohta M, Horii T, Ito H, et al. Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother 1994;38(1): 71-8.
30. Ito H, Arakawa Y, Ohsuka S, Wacharotayankun R, Kato N, Ohta M. Plasmid-mediated dissemination of the metallo-beta-lactamase gene blaIMP among clinically isolated strains of Serratia marcescens. Antimicrob Agents Chemother 1995;39(4):824-9.
31. Senda K, Arakawa Y, Nakashima K, Ito H, Ichiyama S, Shimokata K, et al. Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems. Antimicrob Agents Chemother 1996;40(2):349-53.
32. Poirel L, Lambert T, Turkoglu S, Ronco E, Gaillard J, Nordmann P. Characterization of Class 1 integrons from Pseudomonas aeruginosa that contain the bla(VIM-2) carbapenem-hydrolyzing beta-lactamase gene and of two novel aminoglycoside resistance gene cassettes. Antimicrob Agents Chemother 2001;45(2): 546-52.
33. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002;8(6):321-31.
34. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type beta-lactamases. Antimicrob Agents Chemother 2002;46(1):1-11.
35. Naas T, Nordmann P. OXA-type beta-lactamases. Curr Pharm Des 1999;5(11):865-79.
36. Danel F, Hall LM, Gur D, Livermore DM. OXA-15, an extended-spectrum variant of OXA-2 beta-lactamase, isolated from a Pseudomonas aeruginosa strain. Antimicrob Agents Chemother 1997;41(4):785-90.
37. Minami S, Akama M, Araki H, Watanabe Y, Narita H, Iyobe S, et al. Imipenem and cephem resistant Pseudomonas aeruginosa carrying plasmids coding for class B beta-lactamase. J Antimicrob Chemother 1996;37(3):433-44.
38. Nordmann P, Naas T. Sequence analysis of PER-1 extended-spectrum beta-lactamase from Pseudomonas aeruginosa and comparison with class A beta-lactamases. Antimicrob Agents Chemother 1994;38(1):104-14.
39. Lodge JM, Minchin SD, Piddock LJ, Busby JW. Cloning, sequencing and analysis of the structural gene and regulatory region of the Pseudomonas aeruginosa chromosomal ampC beta-lactamase. Biochem J 1990;272(3):627-31.
40. Cornaglia G, Mazzariol A, Lauretti L, Rossolini GM, Fontana R. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-beta-lactamase. Clin Infect Dis 2000;31(5):1119-25.
41. Walther-Rasmussen J, Johnsen AH, Høiby N. Terminal truncations in amp C beta-lactamase from a clinical isolate of Pseudomonas aeruginosa. Eur J Biochem 1999;263(2):478-85.
42. De Champs C, Poirel L, Bonnet R, Sirot D, Chanal C, Sirot J, et al. Prospective Survey of beta-Lactamases Produced by Ceftazidime-Resistant Pseudomonas aeruginosa Isolated in a French Hospital in 2000. Antimicrob Agents Chemother 2002;46(9):3031-4.
43. Oefner C, D'Arcy A, Daly JJ, Gubernator K, Charnas RL, Heinze I, et al. Refined crystal structure of beta-lactamase from Citrobacter freundii indicates a mechanism for beta-lactam hydrolysis. Nature 1990;343(6255):284-8.
44. Lobkovsky E, Moews PC, Liu H, Zhao H, Frere JM, Knox JR. Evolution of an enzyme activity: crystallographic structure at 2-A resolution of cephalosporinase from the ampC gene of Enterobacter cloacae P99 and comparison with a class A penicillinase. Proc Natl Acad Sci U S A 1993;90(23):11257-61.
45. Usher KC, Blaszczak LC, Weston GS, Shoichet BK, Remington SJ. Three-dimensional structure of AmpC beta-lactamase from Escherichia coli bound to a transition-state analogue: possible implications for the oxyanion hypothesis and for inhibitor design. Biochemistry 1998;37(46):16082-92.
46. Knott-Hunziker V, Petursson S, Jayatilake GS, Waley SG, Jaurin B, Grundstrom T. Active sites of beta-lactamases. The chromosomal beta-lactamases of Pseudomonas aeruginosa and Escherichia coli. Biochem J 1982;201(3):621-7.
47. Page M. The kinetics of non-stoichiometric bursts of beta-lactam hydrolysis catalysed by class C beta-lactamases. Biochem. J. 1993;295:295-304.
48. Jacobs C, Huang LJ, Bartowsky E, Normark S, Park JT. Bacterial cell wall recycling provides cytosolic muropeptides as effectors for beta-lactamase induction. Embo J 1994;13(19):4684-94.
49. Jacobs C, Frere JM, Normark S. Cytosolic intermediates for cell wall biosynthesis and degradation control inducible beta-lactam resistance in gram-negative bacteria. Cell 1997;88(6):823-32.
50. Wiedemann B, Dietz H, Pfeifle D. Induction of beta-lactamase in Enterobacter cloacae. Clin Infect Dis 1998;27 Suppl 1:S42-7.
51. Langaee TY, Dargis M, Huletsky A. An ampD gene in Pseudomonas aeruginosa encodes a negative regulator of AmpC beta-lactamase expression. Antimicrob Agents Chemother 1998;42(12):3296-300.
52. Lodge JM, Piddock LJ. The control of class I beta-lactamase expression in Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 1991;28(2):167-72.
53. Nukaga M, Haruta S, Tanimoto K, Kogure K, Taniguchi K, Tamaki M, et al. Molecular evolution of a class C beta-lactamase extending its substrate specificity. J Biol Chem 1995;270(11):5729-35.
54. Campbell JI, Ciofu O, Høiby N. Pseudomonas aeruginosa isolates from patients with cystic fibrosis have different beta-lactamase expression phenotypes but are homogeneous in the ampC-ampR genetic region. Antimicrob Agents Chemother 1997;41(6):1380-4.
55. Bagge N, Ciofu O, Hentzer M, Campbell JI, Givskov M, Høiby N. Constitutive High Expression of Chromosomal beta-Lactamase in Pseudomonas aeruginosa Caused by a New Insertion Sequence (IS1669) Located in ampD. Antimicrob Agents Chemother 2002;46(11): 3406-11.
56. Ehrhardt AF, Sanders CC, Romero JR, Leser JS. Sequencing and analysis of four new Enterobacter ampD Alleles. Antimicrob Agents Chemother 1996;40(8): 1953-6.
57. Kopp U, Wiedemann B, Lindquist S, Normark S. Sequences of wild-type and mutant ampD genes of Citrobacter freundii and Enterobacter cloacae. Antimicrob Agents Chemother 1993;37(2):224-8.
58. Edlund T, Grundstrom T, Normark S. Isolation and characterization of DNA repetitions carrying the chromosomal beta-lactamase gene of Escherichia coli K-12. Mol Gen Genet 1979;173(2):115-25.
59. Jaurin B, Normark S. Insertion of IS2 creates a novel ampC promoter in Escherichia coli. Cell 1983;32(3): 809-16.
60. Livermore DM, Yang YJ. Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa. J Infect Dis 1987;155(4):775-82.
61. Sanders CC, Gates ML, Sanders WE, Jr. Heterogeneity of class I beta-lactamase expression in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1988;32(12):1893-5.
62. Sanders CC, Bradford PA, Ehrhardt AF, Bush K, Young KD, Henderson TA, et al. Penicillin-binding proteins and induction of AmpC beta-lactamase. Antimicrob Agents Chemother 1997;41(9):2013-5.
63. Jones RN. Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol Infect Dis 1998;31(3):461-6.
64. Kerem B, Kerem E. The molecular basis for disease variability in cystic fibrosis. Eur J Hum Genet 1996;4(2):65-73.
65. Nielsen OH, Schiøtz PO. Cystic fibrosis in Denmark in the period 1945-1981. Evaluation of centralised treatment. Acta Paediatr. Scand. 1982;suppl. 301:107-19.
66. Tsui LC. Cystic fibrosis modifier genes. Pediatric Pulmonology 2000;Suppl.20:150-151.
67. Garred P, Pressler T, Madsen HO, Frederiksen B, Svejgaard A, Høiby N, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999;104(4):431-7.
68. Roomans GM. Pharmacological treatment of the ion transport defect in cystic fibrosis. Expert Opin Investig Drugs 2001;10(1):1-19.
69. Barasch J, al-Awqati Q. Defective acidification of the biosynthetic pathway in cystic fibrosis. J Cell Sci Suppl 1993;17:229-33.
70. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997;88(4):553-60.
71. Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci U S A 1997;94(22):12088-93.
72. Brown RK, Kelly FJ. Evidence for increased oxidative damage in patients with cystic fibrosis. Pediatr Res 1994;36(4):487-93.
73. Döring G, Goldstein W, Botzenhart K, Kharazmi A, Schiøtz PO, Høiby N, et al. Elastase from polymorphonuclear leucocytes: a regulatory enzyme in immune complex disease. Clin Exp Immunol 1986;64(3):597-605.
74. Pedersen SS. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis. APMIS Suppl 1992;28:1-79.
75. Høiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. Acta Pathol Microbiol Scand Suppl 1977;262:1-96.
76. Høiby N, Krogh Johansen H, Moser C, Song Z, Ciofu O, Kharazmi A. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 2001;3(1):23-35.
77. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000;407(6805):762-4.
78. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother 2001;45(4):999-1007.
79. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284(5418):1318-22.
80. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999;37(6):1771-6.
81. Anwar H, Dasgupta MK, Costerton JW. Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob Agents Chemother 1990;34(11): 2043-6.
82. Xu KD, McFeters GA, Stewart PS. Biofilm resistance to antimicrobial agents. Microbiology 2000;146(Pt 3): 547-9.
83. Gilbert P, Brown MRW. Mechanisms of the protection of bacterial biofilms from antimicrobial agents. In: Microbial biofilms: Lappin-Scott, H. M. Costerton, J. W.; 1995. p. 118-130.
84. Nichols WW, Evans MJ, Slack MP, Walmsley HL. The penetration of antibiotics into aggregates of mucoid and non-mucoid Pseudomonas aeruginosa. J Gen Microbiol 1989;135(Pt5):1291-303.
85. Brooun A, Liu S, Lewis K. A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2000;44(3):640-6.
86. Anwar H, Strap JL, Costerton JW. Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy. Antimicrob Agents Chemother 1992;36(7):1347-51 .
87. Döring G, Conway SP, Heijerman HG, Hodson ME, Høiby N, Smyth A, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16(4):749-67.
88. Høiby N. Cystic fibrosis and endobronchial pseudomonas infection. Curr Opin Pediatr 1993;5(3):247-54.
89. Høiby N, Koch C. Maintenance treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Thorax 2000;55(5):349-50.
90. Pedersen SS, Jensen T, Høiby N, Koch C, Flensborg EW. Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients. Acta Paediatr Scand 1987;76(6):955-61.
91. Szaff M, Høiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983;72(5):651-7.
92. Frederiksen B, Lanng S, Koch C, Høiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996;21(3):153-8.
93. Moss RB, Babin S, Hsu YP, Blessing-Moore J, Lewiston NJ. Allergy to semisynthetic penicillins in cystic fibrosis. J Pediatr 1984;104(3):460-6.
94. Koch C, Hjelt K, Pedersen SS, Jensen ET, Jensen T, Lanng S, et al. Retrospective clinical study of hypersensitivity reactions to aztreonam and six other beta-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses. Rev Infect Dis 1991;13 Suppl 7:5608-11.
95. Pleasants RA, Walker TR, Samuelson WM. Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis. Chest 1994;106(4):1124-8.
96. Pedersen SS, Koch C, Høiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986;17(4):505-16.
97. Williams RJ, Livermore DM, Lindridge MA, Said AA, Williams JD. Mechanisms of beta-lactam resistance in British isolates of Pseudomonas aeruginosa. J Med Microbiol 1984;17(3):283-93.
98. Høiby N, Bremmelgaard A, Schouenborg P. In vitro activity of azlocillin, carbenicillin, mezlocillin and piperacillin against Pseudomonas aeruginosa. Scand J Infect Dis Suppl 1981;29:27-30.
99. Giwercman B, Lambert PA, Rosdahl VT, Shand GH, Høiby N. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains. J Antimicrob Chemother 1990;26(2):247-59.
100. Heilesen AM, Permin H, Koch C, Høiby N. Treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin. Scand J Infect Dis 1983;15(3):271-6.
101. Permin H, Koch C, Høiby N, Christensen HO, Møller AF, Møller S. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. J Antimicrob Chemother 1983;12 Suppl A: 313-23.
102. Sanders CC, Sanders WE, Jr. Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Rev Infect Dis 1983;5(4):639-48.
103. Livermore DM. Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods. Eur J Clin Microbiol 1987;6(4):439-45.
104. Jones RN, Baquero F, Privitera G, Inoue M, Wiedemann B. Inducible beta-lactamase-mediated resistance to third-generation cephalosporins. Clin. Microbiol. Infect. 1997;3, Suppl. 1:S7-S20.
105. Römling U, Fiedler B, Bosshammer J, Grothues D, Greipel J, von der Hardt H, et al. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Infect Dis 1994;170(6):1616-21.
106. Ojeniyi B, Petersen US, Høiby N. Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients. Apmis 1993;101(2):168-75.
107. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348(9028):639-42.
108. Jensen T, Pedersen SS, Høiby N, Koch C. Safety of aztreonam in patients with cystic fibrosis and allergy to beta-lactam antibiotics. Rev Infect Dis 1991;13 Suppl 7:S594-7.
109. Giwercman B, Meyer C, Lambert PA, Reinert C, Høiby N. High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment. Antimicrob Agents Chemother 1992;36(1):71-6.
110. Lister PD, Sanders WE, Jr., Sanders CC. Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998;42(7):1610-9.
111. Pedersen SS, Pressler T, Høiby N, Bentzon MW, Koch C. Imipenem/cilastatin treatment of multiresistant Pseudomonas aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother 1985;16(5):629-35.
112. Pedersen SS, Pressler T, Jensen T, Rosdahl VT, Bentzon MW, Høiby N, et al. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Antimicrob Chemother 1987;19(1):101-7.
113. Lepper PM, Grusa E, Reichl H, Hogel J, Trautmann M. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002;46(9):2920-5.
114. Drusano G. Meropenem: laboratory and clinical data. Clin Microbiol Infect 1997;3 Suppl 4:S51-S59.
115. Sanders CC, Sanders WE, Jr., Thomson KS, Iaconis JP. Meropenem: activity against resistant gram-negative bacteria and interactions with beta-lactamases. J Antimicrob Chemother 1989;24 Suppl A:187-96.
116. Ballestero S, Fernandez-Rodriguez A, Villaverde R, Escobar H, Perez-Diaz JC, Baquero F. Carbapenem resistance in Pseudomonas aeruginosa from cystic fibrosis patients. J Antimicrob Chemother 1996;38(1):39-45.
117. Kohler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999;43(2): 424-7.
118. Kohler T, Pechere C. In vitro selection of antibiotic resistance in Pseudomonas aeruginosa. Clin Microbiol Infect 2001;7(Suppl 5):7-10.
119. Pai H, Kim J, Lee JH, Choe KW, Gotoh N. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2001;45(2):480-4.
120. Thomassen MJ, Demko CA, Boxerbaum B, Stern RC, Kuchenbrod PJ. Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis 1979;140(6):873-80.
121. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328(24):1740-6.
122. Smith AL, Ramsey BW, Hedges DL, Hack B, Williams-Warren J, Weber A, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989;7(4):265-71.
123. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340(1):23-30.
124. MacLeod DL, Nelson LE, Shawar RM, Lin BB, Lockwood LG, Dirk JE, et al. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. J Infect Dis 2000;181(3): 1180-4.
125. Miller GH, Sabatelli FJ, Naples L, Hare RS, Shaw KJ. The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin - a new broad-spectrum aminoglycoside. The Aminoglycoside Resistance Study Groups. J Chemother 1995;7 Suppl 2: 31-44.
126. Karlowsky JA, Saunders MH, Harding GA, Hoban DJ, Zhanel GG. In vitro characterization of aminoglycoside adaptive resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996;40(6):1387-93.
127. Jensen T, Pedersen SS, Nielsen CH, Høiby N, Koch C. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Antimicrob Chemother 1987;20(4):585-94.
128. Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338(8769):725-6.
129. Frederiksen B, Koch C, Høiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 1999;28(3):159-66.
130. Preston CAK, Khoury AE, Reid G, Bruce AW, Costerton JW. Pseudomonas aeruginosa biofilms are more susceptible to ciprofloxacin than to tobramycin. Int. J. Antimicrob. Agents 1996;7:251-6.
131. Jalal S, Ciofu O, Høiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2000;44(3): 710-2.
132. Jensen T, Pedersen SS, Garne S, Heilmann C, Høiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19(6):831-8.
133. Rajgopal A, Arundel P, Denton M, Kerr K, Mooney L, Brownlee K, et al. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatric Pulmonology 2000;Suppl. 20:290-291.
134. Moskowitz SM, Burns JL, Nguyen CD, Høiby N, Ernst RK, Miller SI. Polymyxin resistance and lipid A structure of Pseudomonas aeruginosa isolated from colistin-treated and colistin-naive cystic fibrosis patients. Pediatric Pulmonology 2000;Suppl.20:272.
135. Mouton JW, den Hollander JG, Horrevorts AM. Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother 1993;31(6):919-26.
136. Ballestero S, Escobar H, Villaverde R, Elia M, Ojeda-Vargas M, Baquero F. Continuous monitoring of antimicrobial resistance in cystic fibrosis patients. In: Escobar H, Baquero F, Suarez L, editors. Clinical ecology of cystic fibrosis. Madrid: Elsevier Science Publishers; 1993. p. 63-72.
137. Baquero F, Negri MC, Morosini MI, Blazquez J. Antibiotic-selective environments. Clin Infect Dis 1998;27 Suppl 1:S5-11.
138. Fluge G, Ojeniyi B, Høiby N, Digranes A, Ciofu O, Hunstad E, et al. Typing of Pseudomonas aeruginosa strains in Norwegian cystic fibrosis patients. Clin Microbiol Infect 2001;7(5):238-43.
139. Hancock RE, Woodruff WA. Roles of porin and beta-lactamase in beta-lactam resistance of Pseudomonas aeruginosa. Rev Infect Dis 1988;10(4):770-5.
140. Godfrey AJ, Bryan LE, Rabin HR. beta-Lactam-resistant Pseudomonas aeruginosa with modified penicillin-binding proteins emerging during cystic fibrosis treatment. Antimicrob Agents Chemother 1981;19(5): 705-11.
141. Li XZ, Ma D, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance. Antimicrob Agents Chemother 1994;38(8):1742-52.
142. Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 1994;264(5157):382-8.
143. Sanders CC. Chromosomal cephalosporinases responsible for multiple resistance to newer beta-lactam antibiotics. Annu Rev Microbiol 1987;41:573-93.
144. Sanders CC, Sanders WE, Jr. Clinical importance of inducible beta-lactamases in gram-negative bacteria. Eur J Clin Microbiol 1987;6(4):435-8.
145. Cavallo JD, Leblanc F, Fabre R. [Surveillance of Pseudomonas aeruginosa sensitivity to antibiotics in France and distribution of beta-lactam resistance mechanisms: 1998 GERPB study]. Pathol Biol (Paris) 2000;48(5): 472-7.
146. Sanders WE, Jr., Sanders CC. Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev Infect Dis 1988;10(4):830-8.
147. Chen HY, Yuan M, Livermore DM. Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J Med Microbiol 1995;43(4):300-9.
148. Kohler T, Michea-Hamzehpour M, Plesiat P, Kahr AL, Pechere JC. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997;41(11):2540-3.
149. Join-Lambert OF, Michea-Hamzehpour M, Kohler T, Chau F, Faurisson F, Dautrey S, et al. Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of Pseudomonas aeruginosa acute pneumonia in rats. Antimicrob Agents Chemother 2001;45(2):571-6.
150. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, et al. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol 1996;21(4):713-24.
151. Nikaido H. Multidrug efflux pumps of gram-negative bacteria. J Bacteriol 1996;178(20):5853-9.
152. Chuanchuen R, Narasaki CT, Schweizer HP. The MexJK efflux pump of Pseudomonas aeruginosa requires OprM for antibiotic efflux but not for efflux of triclosan. J Bacteriol 2002;184(18):5036-44.
153. Masuda N, Gotoh N, Ishii C, Sakagawa E, Ohya S, Nishino T. Interplay between chromosomal beta-lactamase and the MexAB-OprM efflux system in intrinsic resistance to beta-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999;43(2):400-2.
154. Srikumar R, Tsang E, Poole K. Contribution of the MexAB-OprM multidrug efflux system to the beta-lactam resistance of penicillin-binding protein and beta-lactamase-derepressed mutants of Pseudomonas aeruginosa. J Antimicrob Chemother 1999;44(4):537-40.
155. Ziha-Zarifi I, Llanes C, Kohler T, Pechere JC, Plesiat P. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999;43(2):287-91.
156. Shannon K, King A, Phillips I. Development of resistance to beta-lactam antibiotics during therapy of Pseudomonas aeruginosa infections. Lancet 1982;1(8287): 1466.
157. Shawar RM, MacLeod DL, Garber RL, Burns JL, Stapp JR, Clausen CR, et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999;43(12):2877-80.
158. Liu W, Nikaido H. Contribution of the cell-surface-associated enzyme in the Zimmermann-Rosselet assay of outer membrane permeability of beta-lactam antibiotics. Antimicrob Agents Chemother 1991;35(1):177-9.
159. Michea-Hamzehpour M, Sanchez JC, Epp SF, Paquet N, Hughes GJ, Hochstrasser D, et al. Two-dimensional polyacrylamide gel electrophoresis isolation and microsequencing of Pseudomonas aeruginosa proteins. Enzyme Protein 1993;47(1):1-8.
160. Pages JM, Anba J, Lazdunski C. Conditions leading to secretion of a normally periplasmic protein in Escherichia coli. J Bacteriol 1987;169(4):1386-90.
161. Georgiou G, Shuler ML. Release of periplasmic enzymes and other physiological effects of β-lactamase overproduction in Escherichia coli. Biotechnology and Bioengineering. 1988;32:741-48.
162. Matsumura N, Minami S, Araki H, Hori R, Ogake N, Watanabe Y. Determination of intracellular and extracellular beta-lactamase activities of Pseudomonas aeruginosa after exposure to beta-lactams in vitro and in vivo. J Infect Chemother 2000;6(4):200-5.
163. Beveridge TJ. Structures of gram-negative cell walls and their derived membrane vesicles. J Bacteriol 1999;181(16):4725-33.
164. Kadurugamuwa JL, Beveridge TJ. Natural release of virulence factors in membrane vesicles by Pseudomonas aeruginosa and the effect of aminoglycoside antibiotics on their release. J Antimicrob Chemother 1997;40(5):615-21.
165. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science 2002;295(5559):1487.
166. Beveridge TJ, Kadurugamuwa JL. Periplasm, periplasmic spaces, and their relation to bacterial wall structure: novel secretion of selected periplasmic proteins from Pseudomonas aeruginosa. Microb Drug Resist 1996;2(1):1-8.
167. Kadurugamuwa JL, Clarke AJ, Beveridge TJ. Surface action of gentamicin on Pseudomonas aeruginosa. J Bacteriol 1993;175(18):5798-805.
168. Gradelski E, Fung-Tomc J, Huczko E, Kessler RE. Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations. J Antimicrob Chemother 1993;32 Suppl B:75-80.
169. Matsumoto H, Terawaki Y. Chromosomal location of the genes participating in the formation of β-lactamase in Pseudomonas aeruginosa. In: Drug Resistance in Bacteria. Tokyo: Japan Scientific Press; 1982. p. 207-211.
170. Langaee TY, Gagnon L, Huletsky A. Inactivation of the ampD gene in Pseudomonas aeruginosa leads to moderate-basal-level and hyperinducible AmpC beta-lactamase expression. Antimicrob Agents Chemother 2000;44(3):583-9.
171. Bagge N, Ciofu O, Skovgaard LT, Høiby N. Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing Pseudomonas aeruginosa due to chromosomal beta-lactamase. Apmis 2000;108(9): 589-600.
172. Low AS, MacKenzie FM, Gould IM, Booth IR. Protected environments allow parallel evolution of a bacterial pathogen in a patient subjected to long-term antibiotic therapy. Mol Microbiol 2001;42(3):619-30.
173. Giwercman B, Jensen ET, Høiby N, Kharazmi A, Costerton JW. Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm. Antimicrob Agents Chemother 1991;35(5):1008-10.
174. Dibdin GH, Assinder SJ, Nichols WW, Lambert PA. Mathematical model of beta-lactam penetration into a biofilm of Pseudomonas aeruginosa while undergoing simultaneous inactivation by released beta-lactamases. J Antimicrob Chemother 1996;38(5):757-69.
175. Baquero F, Negri MC. Selective compartments for resistant microorganisms in antibiotic gradients. Bioessays 1997;19(8):731-6.
176. Baquero F, Negri MC. Strategies to minimize the development of antibiotic resistance. J Chemother 1997;9 Suppl 3:29-37.
177. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000;288(5469):1251-4.
178. Ciofu O, Bagge N, Wassermann T, Høiby N. The frequency of mutator P. aeruginosa increases during the chronic lung infection of patients with CF. In: Sixteenth Annual North American Cystic Fibrosis Conference; 2002; New Orleans, Louisiana, USA: Ped. Pulmonol.; 2002. p. 284.
179. Schlosser-Silverman E, Elgrably-Weiss M, Rosenshine I, Kohen R, Altuvia S. Characterization of Escherichia coli DNA lesions generated within J774 macrophages. J Bacteriol 2000;182(18):5225-30.
180. LeClerc JE, Li B, Payne WL, Cebula TA. High mutation frequencies among Escherichia coli and Salmonella pathogens. Science 1996;274(5290):1208-11.
181. Weitzman SA, Stossel TP. Mutation caused by human phagocytes. Science 1981;212(4494):546-7.
182. Torkelson J, Harris RS, Lombardo MJ, Nagendran J, Thulin C, Rosenberg SM. Genome-wide hypermutation in a subpopulation of stationary-phase cells underlies recombination-dependent adaptive mutation. Embo J 1997;16(11):3303-11.
183. Alonso A, Campanario E, Martinez JL. Emergence of multidrug-resistant mutants is increased under antibiotic selective pressure in Pseudomonas aeruginosa. Microbiology 1999;145(Pt 10):2857-62.
184. Giwercman B, Rasmussen JW, Cioufu O, Clemmentsen I, Schumacher H, Høiby N. Antibodies against chromosomal beta-lactamase. Antimicrob Agents Chemother 1994;38(10):2306-10.
185. Giwercman B, Høiby N. IgG antibodies can penetrate Pseudomonas aeruginosa biofilms and inhibit β-lactamase. In: 19th European Cystic Fibrosis Conference; 1994; Paris; 1994.
186. Zhu M, Takenaka S, Sato M, Hoshino E. Extracellular polysaccharides do not inhibit the reaction between Streptococcus mutans and its specific immunoglobulin G (IgG) or penetration of the IgG through S. mutans biofilm. Oral Microbiol Immunol 2001;16(1):54-6.
187. Meno Y, Amako K. Morphological evidence for penetration of anti-O antibody through the capsule of Klebsiella pneumoniae. Infect Immun 1990;58(5):1421-8.
188. Celada F, Strom R. Antibody-induced conformational changes in proteins. Q Rev Biophys 1972;5(3):395-425.
189. Housewright RD, Henry R. The effect of antipenicillinase on penicillin-resistant organisms. J. Bact. 1947;53: 241-247.
190. Pollock MR. Stimulating and inhibiting antibodies for bacterial penicillinase. Immunology 1964;7:707-723.
191. Zyk N, Citri N. The interaction of penicillinase with penicillins. VI. Comparison of free and antibody-bound enzyme. Biochim Biophys Acta 1968;159(2): 317-26.
192. Zyk N, Citri N. The interaction of penicillinase with penicillins. VII. Effect of specific antibodies on conformative response. Biochim Biophys Acta 1968;159(2):327-39.
193. Carrey EA, Virden R, Pain RH. The reversible deactivation of beta-lactamase from Staphylococcus aureus by quinacillin and cephaloridine and its modification by antibodies. Biochim Biophys Acta 1984;785(3):104-10.
194. Chond DV, Goldner M. Inhibition and enhancement of cephalosporin beta-lactamase activity by specific antisera. Can J Microbiol 1970;16(8):647-50.
195. Citri N, Kalkstein A, Samuni A, Zyk N. Conformational adaptation of RTEM beta-lactamase to cefoxitin. Eur J Biochem 1984;144(2):333-8.
196. Bibi E, Laskov R. Selection and application of antibodies modifying the function of beta-lactamase. Biochim Biophys Acta 1990;1035(2):237-41.
197. Connolly AK, Waley SG. Characterization of the membrane beta-lactamase in Bacillus cereus 569/H/9. Biochemistry 1983;22(20):4647-51.
198. Morin CJ, Patel PC, Levesque RC, Letarte R. Monoclonal antibodies to TEM-1 plasmid-mediated beta-lactamase. Antimicrob Agents Chemother 1987;31(11): 1761-7.
199. Bibi E. Purification of TEM-1 beta-lactamase by immunoaffinity chromatography. Biochem J 1989;263(1): 309-11.
200. Hargis JW, Husain SS. Detection of beta-lactamase in Haemophilus influenzae by immunofluorescence. Can J Microbiol 1981;27(10):1076-9.
201. Bernadac A, Bolla JM, Lazdunski C, Inouye M, Pages JM. Precise localization of an overproduced periplasmic protein in Escherichia coli: use of double immuno-gold labelling. Biol Cell 1987;61(3):141-7.
202. Dalhoff A. Synergy between acylureidopenicillins and immunoglobulin G in experimental animals. Am J Med 1984;76(3A):91-100.
203. Lauwereys M, Arbabi Ghahroudi M, Desmyter A, Kinne J, Holzer W, De Genst E, et al. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. Embo J 1998;17(13):3512-20.
204. Conrath KE, Lauwereys M, Galleni M, Matagne A, Frere JM, Kinne J, et al. Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob Agents Chemother 2001;45(10):2807-12.
205. Doring G, Obernesser HJ, Botzenhart K, Flehmig B, Hoiby N, Hofmann A. Proteases of Pseudomonas aeruginosa in patients with cystic fibrosis. J Infect Dis 1983;147(4):744-50.
206. Doring G, Buhl V, Høiby N, Schiøtz PO, Botzenhart K. Detection of proteases of Pseudomonas aeruginosa in immune complexes isolated from sputum of cystic fibrosis patients. Acta Pathol Microbiol Immunol Scand [C] 1984;92(5):307-12.
207. Wood RE. Pseudomonas: the compromised host. Hosp Pract 1976;11(8):91-100.
208. Pressler T. IgG subclasses and chronic bacterial infection. Subclass antibodies and the clinical course of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. APMIS Suppl 1996;66:1-41.
209. Morell A, Vassalli G, DeLange GG, Skvaril F, Ambrosino DM, Siber GR. Ig allotype-linked regulation of class and subclass composition of natural antibodies to group A streptococcal carbohydrate. J Immunol 1989;142(7):2495- 500.
210. Propert D. Immunoglobulin allotypes and RFLPs in disease association. Exp Clin Immunogenet 1995;12(3): 198-205.
211. Pressler T, Jensen ET, Espersen F, Pedersen SS, Høiby N, Koch C. Correlation between specific IgG subclass antibodies to Pseudomonas aeruginosa and opsonic activity in serum from patients with cystic fibrosis. Pediatr Pulmonol 1994;17(1):31-40.
212. Pandey JP, French MA. GM phenotypes influence the concentrations of the four subclasses of immunoglobulin G in normal human serum. Hum Immunol 1996;51(2):99-102.
213. Morrin M, Reen DJ. Role of IgG subclass response to outer-membrane proteins in inhibiting adhesion of Pseudomonas aeruginosa to epithelial cells. J Med Microbiol 1993;39(6):467-72.
214. Likavcanova E, Lagace J. Quantitative analysis of immunoglobulin G subclass responses to Pseudomonas aeruginosa antigens in cystic fibrosis. J Med Microbiol 1992;36(6):437-44.
215. Pressler T, Pandey JP, Espersen F, Pedersen SS, Fomsgaard A, Koch C, et al. Immunoglobulin allotypes and IgG subclass antibody response to Pseudomonas aeruginosa antigens in chronically infected cystic fibrosis patients. Clin. exp. Immunol. 1992;90:209-214.
216. Steward MW. The biological significance of antibody affinity. Immunology today 1981;July:134-140.
217. Griffiths GM, Berek C, Kaartinen M, Milstein C. Somatic mutation and the maturation of immune response to 2-phenyl oxazolone. Nature 1984;312(5991):271- 5.
218. Slifka MK, Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998;10(3):252-8.
219. Devey ME, Bleasdale K, Isenberg DA. Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1987;68(3):562-9.
220. Vermont CL, van Dijken HH, van Limpt CJ, de Groot R, van Alphen L, van Den Dobbelsteen GP. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine. Infect Immun 2002;70(2):584-90.
221. Ghose AC, Karush F. The affinity and temporal variation of isoelectric fractions of rabbit anti-lactose antibody. Biochemistry 1973;12(13):2437-43.
222. Devey ME, Beckman S, Kemeny DM. The functional affinities of antibodies of different IgG subclasses to dietary antigens in mothers and their babies. Clin Exp Immunol 1993;94(1):117-21.
223. Thomas HI, Morgan-Capner P, Cradock-Watson JE, Enders G, Best JM, O'Shea S. Slow maturation of IgG1 avidity and persistence of specific IgM in congenital rubella: implications for diagnosis and immunopathology. J Med Virol 1993;41(3):196-200.
224. Bruderer U, Cryz SJ, Jr., Schaad UB, Deusinger M, Que JU, Lang AB. Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients. J Infect Dis 1992;166(2):344-9.
225. Mascini EM, Jansze M, Verhoef J, van Dijk H. Relative avidities of human immunoglobulin G antibodies for streptococcal pyrogenic exotoxins A and B. Clin Diagn Lab Immunol 1999;6(6):977-80.
226. Devey ME, Bleasdale K, Stanley C, Steward MW. Failure of affinity maturation leads to increased susceptibility to immune complex glomerulonephritis. Immunology 1984;52(2):377-83.
227. Høiby N, Döring G, Schiøtz PO. The role of immune complexes in the pathogenesis of bacterial infections. Annu Rev Microbiol 1986;40:29-53.
228. Lang AB, Schaad UB, Rudeberg A, Wedgwood J, Que JU, Furer E, et al. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Pediatr 1995;127(5):711-7.
229. Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 1995;15(3):279-91.
230. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, et al. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 2000;406(6799):959-64.
231. Vogel U, Claus H. The evolution of human pathogens: examples and clinical implications. Int J Med Microbiol 2000;290(6):511-8.
232. Mathee K, Ciofu O, Sternberg C, Lindum PW, Campbell JI, Jensen P, et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 1999;145(Pt 6):1349-57.
233. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996;60(3):539-74.
234. Passador L, Cook JM, Gambello MJ, Rust L, Iglewski BH. Expression of Pseudomonas aeruginosa virulence genes requires cell-to-cell communication. Science 1993;260(5111):1127-30.
235. Geisenberger O, Givskov M, Riedel K, Høiby N, Tummler B, Eberl L. Production of N-acyl-L-homoserine lactones by P. aeruginosa isolates from chronic lung infections associated with cystic fibrosis. FEMS Microbiol Lett 2000;184(2):273-8.
236. Wu H, Song Z, Hentzer M, Andersen JB, Heydorn A, Mathee K, et al. Detection of N-acylhomoserine lactones in lung tissues of mice infected with Pseudomonas aeruginosa. Microbiology 2000;146(Pt 10): 2481-93.
237. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57(3):212-6.
238. Nagino K, Kobayashi H. Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginosa. Clin Microbiol Infect 1997;3(4): 432-439.
239. Tateda K, Comte R, Pechere JC, Kohler T, Yamaguchi K, Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001;45(6):1930-3.
240. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001;31(6): 464-73.
241. Manefield M, de Nys R, Kumar N, Read R, Givskov M, Steinberg P, et al. Evidence that halogenated furanones from Delisea pulchra inhibit acylated homoserine lactone (AHL)-mediated gene expression by displacing the AHL signal from its receptor protein. Microbiology 1999;145(Pt 2):283-91.
242. Renau TE, Leger R, Flamme EM, Sangalang J, She MW, Yen R, et al. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J Med Chem 1999;42(24):4928-31.
243. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001;45(1): 105-16.
244. Coleman K, Griffin DR, Page JW, Upshon PA. In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor. Antimicrob Agents Chemother 1989;33(9):1580-7.
245. Babini GS, Livermore DM. Effect of conalbumin on the activity of Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC beta-lactamases. J Antimicrob Chemother 2000;45(1):105-9.
246. Li XZ, Zhang L, Srikumar R, Poole K. Beta-lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998;42(2):399-403.
247. Powers RA, Blazquez J, Weston GS, Morosini MI, Baquero F, Shoichet BK. The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase. Protein Sci 1999;8(11):2330-7.
248. Good L, Nielsen PE. Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nat Biotechnol 1998;16(4):355-8.
249. Sokol PA, Kooi C, Hodges RS, Cachia P, Woods DE. Immunization with a Pseudomonas aeruginosa elastase peptide reduces severity of experimental lung infections due to P. aeruginosa or Burkholderia cepacia. J Infect Dis 2000;181(5):1682-92.